Andrew Halpert

Andrew Halpert has worked in the medical technology industry since 1998. Andrew began their career as a Software Engineer at Dobelle Institute, where they led a team of interns in the development of three generations of Artificial Vision systems for the blind. In 2000, they joined CHF Solutions as a Senior Software Engineer, where they developed software, documentation, and testing to support a successful 510 (k) application and CE approval. Andrew also worked with users to significantly improve the user interface of the device and managed the development of an advanced prototype used to complete a pilot pre-clinical study for proof of concept. In 2004, they joined Coridea as a Senior Software Engineer, where they developed the initial prototype of the RenalGuard system for pre-clinical testing and used the experience to significantly increase the reliability and usability of the system. Andrew also developed the technology and co-wrote the original patent for the technology that is now the basis of a $50M+ startup. In the same year, they joined 3D Learner as the Director of Marketing. In 2006, they joined RenalGuard Solutions, Inc. as the Chief Technology Officer, President, Director of Marketing, Engineering, and Clinical, Director of Engineering, and Systems Engineer. In 2018, they joined Reprieve Cardiovascular as the VP of R&D.

Andrew Halpert attended Marjory Stoneman Douglas High School, followed by the American School in London. Andrew then went on to complete a BS in Electrical Engineering from Columbia University in 2000. In 2007, they earned an MBA in Entrepreneurship from Babson F.W. Olin Graduate School of Business.